ESC 365 - Advantage of novel oral anticoagulants compared to vitamin-K antagonist in atrial fibrillation. Data from real world.

ESC Premium Access

Advantage of novel oral anticoagulants compared to vitamin-K antagonist in atrial fibrillation. Data from real world.

Session: Poster Session 5 - Atrial fibrillation - Stroke prevention 2

Topic: Oral Anticoagulation

Speaker: Doctor G. Simonyi (Budapest, HU)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Gabor Antal Simonyi

St Imre University Teaching Hospital, Budapest (Hungary)

0 follower

10 more presentations in this session

Antithrombotic management in patients with atrial fibrillation and acute coronary syndromes

Speaker: Associate Professor B. Hudzik (Zabrze, PL)

Prior antithrombotic therapy: a snapshot of 17,769 patients from the global edoxaban treatment in routine clinical practice in patients with non-valvular atrial fibrillation programme (global ETNA-AF)

Speaker: Professor R. De Caterina (Pisa, IT)

Oral anticoagulation continuation vs. discontinuation after catheter-ablation of paroxysmal atrial fibrillation - incidence of cerebral insults and severe hemorrhagic complications

Speaker: Ms L. Pracht (Munich, DE)

A new score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs

Speaker: Doctor O. Rutherford (Sarpsborg, NO)

Difference of efficacy and safety of left atrial appendage closure using watchman between patients aged less than 75 to more than 75 years

Speaker: Doctor J. Yu (Lichtenfels, DE)

Access the full session

Poster Session 5 - Atrial fibrillation - Stroke prevention 2

Speakers: Doctor G. Simonyi, Associate Professor B. Hudzik, Professor R. De Caterina, Ms L. Pracht, Doctor O. Rutherford...

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources